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abstRact
Background and Aims:  bioactive glass s53p4 is an antibacterial bone substitute with 
bone-bonding and osteostimulative properties. the bone substitute has been successfully 
used clinically in spine; trauma; orthopedic; ear, nose, and throat; and cranio-maxillofacial 
surgeries. bioactive glass s53p4 significantly reduces the amount of bacteria in vitro and 
possesses the capacity to kill both planktonic bacteria and bacteria in biofilm. three patients 
with severe spondylodiscitis caused by Mycobacterium tuberculosis, Candida tropicalis, 
or Staphylococcus aureus were operatively treated due to failed conservative treatment. 
the vertebral defects were reconstructed using bioactive glass s53p4 and an expandable 
replacement device.
Material and Methods: decompression and a posterolateral spondylodesis, using 
transpedicular fixation, were performed posteriorly in combination with an anterior 
decompression and reconstruction using an expandable vertebral body replacement 
device. for patients 1 and 2, the expander was covered with bioactive glass s53p4 only, 
and for patient 3, the glass was mixed with autograft bone.
Results: the patients healed well with complete neurological recovery. fusion was observed 
for all patients. the total follow-up was 4 years for patient 1, 1 year and 8 months for patient 2, 
and 2 years and 2 months for patient 3. no relapses or complications were observed.
Conclusion: the antibacterial properties of bioactive glass s53p4 also make it a suitable 
bone substitute in the treatment of severe spondylodiscitis.
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INTRODUCTION
Pyogenic vertebral osteomyelitis (VO) is a rare con-
dition. In the developed countries, a steady increase 
in VO related to the aging population has, however, 
been observed. The incidence of VO has been esti-
mated to be 2.4 per 100,000, increasing to 6.5 per 
100,000 among people >70 years of age (1). The path-
ogen causing VO is most often Staphylococcus aureus. 
VO is usually caused by hematogenous seeding, but 
it can also be related to spinal surgery or originate 
from a nearby infection (2). In cases of suspected 
VO, magnetic resonance imaging (MRI) is recom-
mended. The diagnostic sensitivity is 82% and the 
specificity 53%–94%. Usually, the infection involves 
a disk space, the epicenter of the pathologic change, 
and two adjacent vertebral bodies (3).
Hematogenous VO can usually be treated suc-
cessfully with antibiotics. Complications compris-
ing epidural or psoas abscess formations, which are 
common findings, may need surgical drainage (1). 
In some patients, the infection causes large bony 
defects leading to instability and pathological frac-
tures, resulting in the need for stabilization and 
reconstruction of the lost vertebral bone. Using 
metal implants and bone substitutes in infected 
fields is controversial. However, acute placement of 
spinal instrumentation has not been associated 
with recurrent infections (4–9).
In most patients, bone grafts are needed. a (BAG) 
S53P4, consisting of 53% SiO2, 23% Na2O, 20% CaO, 
and 4% P2O5, is an antibacterial, bone-bonding, and 
osteoconductive bone substitute, with osteogenetic 
and angiogenetic stimulating properties. BAG S53P4 
has successfully been used in the filling of cavitary 
defects in the treatment of demanding osteomyelitis 
(10, 11), mastoiditis, and chronic frontal sinusitis for 
more than 10 years (12–15). Here, the operative tech-
nique and the long-term outcome of a reconstruction 
and stabilization method, using internal fixation and 
BAG S53P4 in the treatment of three demanding cases 
with verified severe VO caused by three different 
pathogens, are reported.
MATERIALS AND METHODS
Patient 1 (female, 80 years of age) suffered from dif-
fuse low back pain in 2007. Spondylodiscitis affecting 
lumbar vertebrae L3 and L4 and paravertebral and 
epidural abscess formations were observed on MRI. 
The patient was treated conservatively with antibiot-
ics for 2 years without success. Progressive lytic 
destructions of vertebrae L3 and L4 were observed, 
despite the conservative treatment. The patient 
needed a rollator for walking because of weakness of 
the lower extremities (Frankel D), and in bed the neu-
rological status was normal. The indication for oper-
ative treatment was progressive lytic deformities. In 
2009, a posterior decompression of L2/3–L3/4, a 
posterolateral spondylodesis of L2–L5, using trans-
pedicular fixation with an Omega 21 device (titanium 
alloy; Biomet Inc., Warsaw, IN, USA), in combination 
with lumbotomy and canalization of paravertebral 
abscesses, resection of vertebral bodies of L3–L4, and 
anterior decompression and reconstruction from L2 
to L5, using a Synex 2 device (titanium alloy; Synthes 
Inc., Solothurn, Switzerland), were performed. The 
expander was covered with 0.8–1.0-mm BAG S53P4 
granules (BonAlive Biomaterials, Ltd, Turku, 
Finland) (volume: 32 mL). Before the operation, no 
pathogen had been identified. Postoperatively, we 
confirmed by samples taken during the operation 
that the patient suffered from an infection caused by 
Mycobacterium tuberculosis.
Patient 2 (male, 53 years of age, a narcotic addict with 
hepatitis C) suffered from back pain, progressive kypho-
sis, and numbness in the lower extremities since 2006. 
Spondylodiscitis affecting L3 and L4 and destruction of 
L2–L4 were verified on MRI. Bone computed tomogra-
phy (CT) biopsy confirmed that the patient suffered 
from the pathogen Candida tropicalis. He was treated 
conservatively without success, and the bodies of verte-
brae L3 and L4 were completely destroyed, as well as 
the lower part of L2. He walked with crutches and 
showed some signs of cauda equina syndrome (Frankel 
D). In 2010, a posterior decompression of L2/3–L4/5, 
reduction, and posterolateral spondylodesis using a 
transpedicular Omega 21 device were performed. BAG 
S53P4 granules 2.0–3.15 mm in size (volume: 16 mL) 
were mixed with autologous bone and placed postero-
laterally. In a second operation 5 days later, the bodies of 
L3 and L4 were resected and an anterior reconstruction 
was performed using an expandable replacement device 
(Obelisc, titanium alloy; Ulrich Medical GmbH & Co. 
KG, Ulm, Germany). The end holes of the implant were 
packed and the entire implant covered with 1.0–2.0 mm 
BAG S53P4 granules (volume: 20 mL) without any 
autologous bone transplant.
Patient 3 (male, 72 years of age, usually healthy) had 
acute back pain and fever in 2010. In 2 weeks, he devel-
oped cauda equina syndrome and paralysis of the 
lower left extremity. MRI revealed spondylodiscitis 
affecting the thoracic vertebrae T6–T8. A hemilaminec-
tomy-type minor decompression was done and 
repeated twice during 9 days in another institute with-
out any success. S. aureus was cultured in the specimens 
taken during the operations. Before the first operation, 
the patient was classified as Frankel D and after the 
third operation Frankel C with total cauda equina syn-
drome. At that stage, the patient was referred to our 
clinic, and a posterior decompression of vertebrae T6–
T7 (laminectomia totalis) and a posterolateral spondy-
lodesis of T4, T5, T8, andT9, using a transpedicular 
fixator (titanium alloy; Diapason; Stryker Corp., 
Kalamazoo, MI, USA), were performed. BAG S53P4 
particles 2.0–3.15 mm in size (volume: 10 mL) mixed 
with healthy-looking pieces of the laminectomy bone 
were placed posterolaterally on both sides. The opera-
tion then continued with a right-sided thoracotomy, a 
resection of the vertebral bodies of T6–T7, an anterior 
decompression, and a reconstruction using an Obelisc 
expandable vertebral body replacement device. BAG 
S53P4 mixed with autologous rib bone was placed into 
the end holes of the implant. Part of the rib was placed 
as a block in the side of the implant, and the rest of the 
mixture of BAG/crushed rib was placed in the sides 
and in front of the implant.
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RESULTS
All patients recovered from the infection, and no 
reinfections were noted during the follow-up. The 
total follow-up was 4 years (patient 1), 1 year and 
8 months (patient 2), and 2 years and 2 months 
(patient 3). For patient 1, a small psoas abscess for-
mation was observed postoperatively; no further 
operative treatment was, however, needed and the 
abscess formation disappeared spontaneously. The 
antibiotic therapy lasted 6 months for patient 1. 
Patient 2 was prescribed continuous diflucan treat-
ment. Patient 3 was prescribed antibiotic treatment 
for 2 years and 2 months. The postoperative plasma 
C-reactive protein (P-CRP) level was 279 mg/L 
(patient 1), 139 mg/L (patient 2), and 21 mg/L 
(patient 3). The C-reactive protein (CRP) value 
became and remained normal for all patients.
All three patients showed full neurologic recovery 
and underwent spinal fusion during follow-up. 
Excellent radiological results with total fusion were 
observed for all patients. The pre- and postoperative 
radiological findings for patient 3 are shown in Figs 1 
to 5. In patient 1, BAG S53P4 alone was placed around 
the vertebral body replacement device. CT revealed 
that the entire region was completely fused. In patients 
2 and 3, BAG S53P4 was also placed at the end holes of 
the device. CT in patient 3 revealed that the inside of 
the device was completely filled with bone. Patients 1 
and 2 received only BAG in the anterior part of the 
spine, while patient 3 received a mixture of BAG and 
crushed autologous bone from the ribs. Patient 2 later 
died of acute leukemia.
DISCUSSION
Surgical management of VO is demanding, espe-
cially in cases comprising large bony defects. Using 
implants, mainly of titanium, in the treatment of VO 
has been associated with low long-term recurrence 
risk. To use any type of implant in infected regions is, 
however, controversial because pathogens are able to 
produce biofilms on the surface of the implanted 
materials, thus complicating the treatment outcome. 
Several methods have been developed for recon-
struction of destroyed vertebrae, including expanda-
ble replacement devices and cages. Fusion is usually 
promoted using auto- or allografts. The use of auto-
grafts is associated with morbidity at the donor site, 
and especially in children and adolescents, the avail-
ability of graft material can be limited. Allograft bone 
is associated with resorption and the possibility of 
spread of infections.
Use of synthetic bone grafts and implanted materi-
als in treating osteomyelitis is generally not recom-
mended. Bacterial colonization on implanted 
materials, with subsequent formation of biofilms, may 
hinder antibiotic treatment and recovery. However, 
BAG S53P4 significantly reduces S. aureus and 
Pseudomonas aeruginosa biofilm formation on titanium 
disks in vitro (16). Marked bactericidal activity of BAG 
S53P4 against methicillin-resistant S. aureus, 
Staphylococcus epidermidis, and Pseudomonas aeruginosa 
have been observed in vitro (11). Studies of atrophic 
rhinitis, a purulent disorder often caused by Klebsiella 
ozaenae, have shown that BAG S53P4 does not favor 
adhesion, colonization, or biofilm formation of K. ozae-
nae on its surface (17). Clinically, BAG S53P4 has been 
used as a bone graft substitute in cavitary defects in 
the treatment of osteomyelitis, with excellent clinical 
results (10, 11). In the majority of patients, the proce-
dure has been performed using BAG S53P4 in a one-
stage procedure.
The antibacterial effect of BAG S53P4 is well estab-
lished. The properties of the glass have been associ-
ated with the initial leaching of alkali and alkaline-earth 
ions from the glass surface, starting immediately after 
implantation. The dissolution process is characterized 
Fig. 1. Patient 3, preoperative CT.
Fig. 2. Patient 3, preoperative MRI.
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Fig. 3. (a, b) Patient 3, postoperative X-ray at 3 months.
Fig. 4. (a, b) Patient 3, postoperative CT at 2 years and 2 months.
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by a rapid exchange of Na+ in the glass with H+ from 
the solution, resulting in a subsequent increase in pH. 
The high pH, which in a simulated body fluid, 
increases to a pHmax value of 11, and the osmotic pres-
sure in the vicinity of the implanted glass granules 
may explain the antibacterial effect of BAG. Comparing 
the bactericidal effect of BAG S53P4 with that of sev-
eral other glasses has shown that BAG S53P4 is the 
most effective, with the fastest killing and growth 
inhibitory effect. This has been observed for 29 aerobic 
and 17 anaerobic pathogens tested, including multire-
sistant pathogens (18–21).
The antibacterial effect is dependent on not only 
the glass composition but also the granule size. 
Comparing the in situ pH within the particles of 
BAGs in vitro has shown a relationship between pH 
and glass granule size. An increase in granule size 
corresponding to a decrease in pH, explained by a 
decrease in surface area, was observed (21). Various 
sizes of BAG S53P4 particles were used in our 
patients. For patient 1, a small granule size was cho-
sen to achieve a large surface area. The same clinical 
results were, however, achieved despite the differ-
ences in granule size used.
In this study, fusion was observed for all patients 
both when used alone and as a mixture with autolo-
gous bone. A weakness in this study is that the total 
follow-up for patient 2 did not have a formal 2-year 
follow-up due to the death of the patient. In spinal 
surgery, long-term results using BAG S53P4 as a 
stand-alone bone substitute in instrumented poste-
rolateral spondylodesis revealed a fusion rate of 
88% in the treatment of spondylolisthesis and a 
fusion rate of 71% in the treatment of unstable lum-
bar fractures (22, 23). We, therefore, recommend 
that S53P4 be used as an expander combined with 
autologous bone. We also demonstrated that a 
favorable outcome can be achieved using antibacte-
rial BAG S53P4 as a bone graft substitute in the 
treatment of severe VO.
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